Leaderboard
Insiders and issuers ranked by realized signed return on open-market Form 4 trades. Returns are signed: a sale followed by a rally counts against the seller.
What the metrics mean
Return - the insider's signed return per trade, averaged. A +10% stock move on a buy scores +10%; on a sell, -10%. Because most insider activity is concentrated at rallying stocks, this metric correlates with raw stock performance and doesn't fully isolate timing skill from market drift.
Edge - signed return minus the stock's average forward N-day return over the same period. An insider with +5% edge consistently chose better days to trade than someone who'd picked a random day in the same window. Isolates timing skill from "the stock just went up."
Neither metric is the same as ranking stocks by raw return - that would just surface the best-performing tickers, which you can get from any market screener.
Issuers ranked
3,504
Showing 50 of 3,504
Quality filters
10+ trades
≥3 insiders, 50% price coverage
Window
5y trailing
Trade date filter
| # | Ticker | Issuer | Trades | Insiders | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|---|---|
| 51 | LIDR | Aeye, Inc. | 47 | 9 | 85% | +31.5% | +37.3% | +68.4% | -16.5% |
| 52 | TCRX | Tscan Therapeutics, Inc. | 81 | 13 | 77% | +31.4% | +50.5% | +52.3% | -31.7% |
| 53 | OPTT | Ocean Power Technologies, Inc. | 11 | 4 | 55% | +31.4% | +2.0% | +150.0% | -20.5% |
| 54 | HBIO | Harvard Bioscience Inc | 15 | 6 | 80% | +31.3% | +14.6% | +88.8% | -6.4% |
| 55 | LFMD | Lifemd, Inc. | 37 | 10 | 76% | +31.2% | +20.7% | +121.1% | -77.2% |
| 56 | ELYM | Eliem Therapeutics, Inc. | 49/60 | 11 | 88% | +30.7% | +13.7% | +104.3% | -22.6% |
| 57 | TOI | Oncology Institute, Inc. | 84/87 | 19 | 85% | +29.3% | +12.2% | +173.6% | -19.5% |
| 58 | BURU | Nuburu, Inc. | 652 | 12 | 100% | +29.2% | +29.2% | +45.3% | -13.8% |
| 59 | SANA | Sana Biotechnology, Inc. | 95 | 24 | 97% | +29.1% | +30.5% | +54.2% | -58.6% |
| 60 | ZSPC | Zspace, Inc. | 32 | 5 | 94% | +28.9% | +19.9% | +93.4% | -89.2% |
| 61 | MPLN | Multiplan Corp | 78/87 | 17 | 91% | +28.9% | +36.1% | +80.1% | -38.1% |
| 62 | RLYB | Rallybio Corp | 62/86 | 13 | 97% | +28.8% | +29.5% | +51.8% | -56.8% |
| 63 | EAF | Graftech International Ltd | 1,285 | 28 | 99% | +28.7% | +28.4% | +58.9% | -41.4% |
| 64 | ASST | Asset Entities Inc. | 33 | 12 | 94% | +28.3% | +33.5% | +53.9% | -60.3% |
| 65 | AMST | Amesite Inc. | 10 | 3 | 80% | +28.3% | +19.1% | +75.5% | -8.1% |
| 66 | AIM | Aim Immunotech Inc. | 34 | 6 | 41% | +28.0% | 0.0% | +233.3% | -30.8% |
| 67 | CDT | Conduit Pharmaceuticals Inc. | 54 | 7 | 78% | +28.0% | +35.5% | +68.6% | -7.0% |
| 68 | FXLV | F45 Training Holdings Inc. | 32 | 3 | 100% | +27.8% | +23.3% | +48.4% | +11.1% |
| 69 | MNTN | Mntn, Inc. | 18 | 15 | 100% | +27.8% | +31.4% | +31.4% | +8.3% |
| 70 | VAXX | Vaxxinity, Inc. | 70 | 7 | 87% | +27.8% | +32.9% | +57.2% | -36.2% |
| 71 | ECOR | Electrocore, Inc. | 30/33 | 7 | 77% | +27.5% | +16.7% | +110.0% | -27.6% |
| 72 | ORMP | Oramed Pharmaceuticals Inc. | 11 | 6 | 91% | +27.5% | +25.3% | +83.4% | -9.6% |
| 73 | VERO | Venus Concept Inc. | 80/88 | 16 | 95% | +27.0% | +30.4% | +41.8% | -25.8% |
| 74 | SCLX | Scilex Holding Co | 19 | 9 | 47% | +26.5% | -2.2% | +147.1% | -35.3% |
| 75 | WLTH | Wealthfront Corp | 15 | 12 | 100% | +26.5% | +26.5% | +26.5% | +26.5% |
| 76 | TRDA | Entrada Therapeutics, Inc. | 354/355 | 32 | 82% | +26.4% | +26.4% | +94.7% | -49.8% |
| 77 | AKBA | Akebia Therapeutics, Inc. | 86 | 12 | 84% | +26.4% | +18.1% | +66.6% | -11.6% |
| 78 | COOK | Traeger, Inc. | 41 | 3 | 95% | +26.1% | +29.6% | +39.8% | -11.7% |
| 79 | RDZN | Roadzen Inc. | 34 | 3 | 53% | +25.6% | +6.7% | +215.4% | -55.3% |
| 80 | PRST | Presto Automation Inc. | 31 | 8 | 87% | +25.6% | +30.0% | +98.2% | -37.3% |
| 81 | GCO | Genesco Inc | 31 | 10 | 90% | +25.5% | +38.0% | +40.1% | -13.0% |
| 82 | STKS | One Group Hospitality, Inc. | 52 | 9 | 81% | +25.3% | +33.2% | +42.6% | -19.2% |
| 83 | FULC | Fulcrum Therapeutics, Inc. | 43 | 8 | 81% | +24.6% | +23.2% | +66.5% | -31.6% |
| 84 | UAMY | United States Antimony Corp | 16 | 5 | 50% | +23.8% | -0.3% | +215.8% | -22.5% |
| 85 | BEAT | Heartbeam, Inc. | 31 | 9 | 87% | +23.7% | +18.4% | +47.4% | -0.9% |
| 86 | ROLR | High Roller Technologies, Inc. | 30 | 9 | 50% | +23.0% | -7.8% | +787.0% | -44.1% |
| 87 | AREC | American Resources Corp | 169 | 4 | 89% | +22.9% | +29.9% | +38.3% | -97.6% |
| 88 | RZLT | Rezolute, Inc. | 60 | 9 | 80% | +22.9% | +26.7% | +73.0% | -75.9% |
| 89 | INMB | Inmune Bio, Inc. | 14 | 5 | 86% | +22.8% | +31.3% | +49.7% | -20.5% |
| 90 | SCWO | 374water Inc. | 71 | 12 | 83% | +22.8% | +35.9% | +51.2% | -70.7% |
| 91 | UA | Under Armour, Inc. | 60/66 | 12 | 83% | +22.7% | +20.9% | +41.7% | -21.9% |
| 92 | DOUG | Douglas Elliman Inc. | 38 | 7 | 79% | +22.7% | +14.3% | +92.4% | -32.5% |
| 93 | UP | Wheels Up Experience Inc. | 24/29 | 15 | 79% | +22.6% | +27.3% | +53.0% | -32.4% |
| 94 | MRVI | Maravai Lifesciences Holdings, Inc. | 16 | 13 | 88% | +22.5% | +34.3% | +38.7% | -0.7% |
| 95 | MDRX | Veradigm Inc. | 118 | 15 | 97% | +22.3% | +27.2% | +30.2% | -6.1% |
| 96 | JSPR | Jasper Therapeutics, Inc. | 54 | 33 | 78% | +22.1% | +9.8% | +67.3% | -26.9% |
| 97 | FIG | Figma, Inc. | 179/188 | 27 | 78% | +22.0% | +30.8% | +46.3% | -46.3% |
| 98 | USEG | US Energy Corp | 296 | 9 | 87% | +22.0% | +23.5% | +163.2% | -37.9% |
| 99 | NRXS | Neuraxis, Inc | 11 | 6 | 82% | +21.9% | +12.5% | +78.3% | -10.1% |
| 100 | BSLK | Bolt Projects Holdings, Inc. | 24 | 6 | 79% | +21.7% | +41.7% | +73.2% | -131.7% |